From Our Partners
Tuesday, June 28, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

EPFL’s Portable Rapid Microfluidic Device

by Global Biodefense Staff
February 23, 2016
EPFL Microfluidic Diagnostic System

Low-cost microfluidic diagnostic system developed at EPFL. Credit: Alban Kakulya

Over the past several years, microfluidic devices have shown extraordinary potential in the area of diagnostics with potential utility for resource-limited areas and epidemic biosurveillance.

At the Ecole Polytechnique Fédérale De Lausanne (EPFL) research organization in Lausanne, Switzerland, a new type of microfluidic platform has come out of the Laboratory of Biological Network Characterization (LBNC), headed by Sebastian Maerkl. The portable device runs on battery power, is completely self-sustained, and operates seamlessly with inexpensive microscopes to provide very high levels of accuracy and detection.

The platform, which is described in a recent ACS Nano article, can quantify up to 16 different molecules – or biomarkers – in a tiny amount of blood (less than 0.005 milliliters). The biomarkers are usually enzymes, proteins, hormones or metabolites and the concentration of these molecules in the blood provides precise information on the patient’s health condition.

The low-cost device has already been tested on Ebola and can be used to detect many other diseases. “The platform will lead the development of new kinds of tests to meet the increasing demand for on-site diagnostic testing. It will prove very useful for medical staff working in resource-limited regions,” said Francesco Piraino, the article’s lead author.

The research team found that they could load blood samples directly onto the device and perform on-chip biomarker quantitation without requiring any sample pre-treatment. “For researchers, it is quite interesting to be able to avoid having to separate the blood,” said Francesco Piraino, the article’s lead author. Blood plasma separation requires centrifuges, large volume samples and a long processing time.

The device also unique in that it is composed of both analog and digital detection mechanisms, while conventional devices hitherto only integrated one or the other. Digital detection is highly sensitive and can detect the presence of a single biomarker. However, it is less effective when the concentration of biomarkers is too high, due to signal saturation.

Analog measurements, on the other hand, function best at higher biomarker concentrations. Using these two detection mechanisms simultaneously, the composition of a drop of blood can be thoroughly analyzed in a short amount of time. The analysis provides precious medical information: it could help doctors make an early diagnosis or determine the stage of a disease.

From Our Partners
Tags: BiomarkersPOC Diagnostics

Related Posts

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies
Biosurveillance

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
The Bioethics and Biosecurity Aspects of Targeted Wastewater Surveillance
Biosurveillance

The Bioethics and Biosecurity Aspects of Targeted Wastewater Surveillance

June 9, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC